Boston Scientific Corporation $BSX Shares Sold by Fisher Asset Management LLC

Fisher Asset Management LLC lessened its position in shares of Boston Scientific Corporation (NYSE:BSX – Free Report) by 12.4% in the third quarter, Holdings Channel reports. The fund owned 292,236 shares of the medical equipment provider’s stock after selling 41,292 shares during the quarter. Fisher Asset Management LLC’s holdings in Boston Scientific were worth $12,756,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Natural Investments LLC grew its stake in shares of Boston Scientific by 1.3% during the 2nd quarter. Natural Investments LLC now owns 16,067 shares of the medical equipment provider’s stock valued at $685,000 after purchasing an additional 206 shares during the period. MGO One Seven LLC increased its stake in shares of Boston Scientific by 1.9% in the third quarter. MGO One Seven LLC now owns 14,061 shares of the medical equipment provider’s stock worth $614,000 after purchasing an additional 260 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich lifted its stake in shares of Boston Scientific by 1.4% during the 3rd quarter. Bank Julius Baer & Co. Ltd Zurich now owns 19,918 shares of the medical equipment provider’s stock valued at $870,000 after buying an additional 268 shares in the last quarter. Great Waters Wealth Management grew its holdings in Boston Scientific by 3.7% during the 3rd quarter. Great Waters Wealth Management now owns 7,823 shares of the medical equipment provider’s stock valued at $341,000 after buying an additional 276 shares in the last quarter. Finally, Bfsg LLC boosted its stake in Boston Scientific by 3.7% during the third quarter. Bfsg LLC now owns 7,867 shares of the medical equipment provider’s stock valued at $343,000 after buying an additional 284 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on BSX. Oppenheimer cut shares of Boston Scientific from an “outperform” rating to a “market perform” rating in a research note on Thursday, October 29th. Stifel Nicolaus cut their target price on shares of Boston Scientific from $60.00 to $55.00 and set a “buy” rating on the stock in a research report on Monday, October 26th. Needham & Company LLC reduced their price target on shares of Boston Scientific from $57.00 to $48.00 and set a “buy” rating for the company in a report on Wednesday, October 28th. Sanford C. Bernstein lowered their price target on shares of Boston Scientific from $54.00 to $49.00 and set an “outperform” rating for the company in a research report on Thursday, October 29th. Finally, Deutsche Bank set a $48.00 price objective on shares of Boston Scientific and gave the company a “buy” rating in a research note on Thursday, October 29th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Boston Scientific presently has an average rating of “Moderate Buy” and an average price target of $61.43.

View Our Latest Analysis on BSX

Boston Scientific Price Performance

Shares of BSX opened at $44.33 on Monday. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.36 and a quick ratio of 0.81. The company’s fifty day moving average price is $44.00 and its 200-day moving average price is $54.50. Boston Scientific Corporation has a 1-year low of $39.57 and a 1-year high of $104.61. The firm has a market capitalization of $64.25 billion, a PE ratio of 18.78, a price-to-earnings-growth ratio of 1.31 and a beta of 0.60.

Boston Scientific (NYSE:BSX – Get Free Report) last issued its earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.73. Boston Scientific had a return on equity of 18.61% and a net margin of 16.62%. The company had revenue of $5.14 billion during the quarter, compared to analyst estimates of $5.09 billion. During the same quarter last year, the business posted $0.75 EPS. The firm’s quarterly revenue was up 1.4% on a year-over-year basis. On average, equities research analysts predict that Boston Scientific Corporation will post 3.17 EPS for the current year.

About Boston Scientific

(Free Report)

Boston Scientific is a medical technology company that develops, manufactures and markets devices used in minimally invasive procedures across a range of medical specialties. Founded in 1979, the company is headquartered in Marlborough, Massachusetts. Its products support areas including cardiovascular care, endoscopy, urology and neuromodulation. They include catheter-based devices and therapies for conditions affecting the heart and blood vessels, as well as devices used in diagnostic and therapeutic procedures involving the digestive and urinary systems.

See Also

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX – Free Report).

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.